BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

Two of China’s most prominent immuno-oncology companies made moves this week to bolster their CAR T cell therapy pipelines: one via a deal and the other with a financing. Innovent Biologics Inc. (HKSE:1801) has acquired...
BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

The failure of Newron’s sarizotan in Rett syndrome leaves the company with two pipeline programs, but its valuation is now trading near its cash position -- a sign that investors see little value in what...
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | Jul 25, 2019
Product Development

The universe of universal flu vaccines

...hemagglutinin; M1 - Influenza virus matrix protein M1; M2 - Influenza virus matrix protein M2; NP...
...hemagglutinin; M1 - Influenza virus matrix protein M1; M2 - Influenza virus matrix protein M2; NP...
...B strains, consists of nine peptides from conserved regions of three major influenza proteins, HA, NP...
BioCentury | Mar 4, 2019
Distillery Therapeutics

Itaconic acid-based NP inhibitor for influenza A

...INDICATION: Influenza virus Cell culture studies identified an itaconic acid-based inhibitor of influenza A virus NP...
...steps could include testing the compound in animal models of influenza A virus infection. TARGET/MARKER/PATHWAY: Influenza A virus nucleoprotein (NP)...
...Taoyuan, Taiwan email: jimtong@mail.cgu.edu.tw CONTACT: Pei-Wen Hsieh, same affiliation as above email: pewehs@mail.cgu.edu.tw Claire Quang Chang Gung University Influenza A virus nucleoprotein (NP) Influenza...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Autoimmune disease

...tumors and preclinical testing for leukemia and depression. Neuro Pharmalogics Inc. has the PP2A inhibitor NP-101...
BioCentury | Dec 14, 2018
Clinical News

Netris' NTN1 inhibitor safe in Phase I for solid tumors

Netris Pharma S.A.S. (Lyon, France) said escalating doses of up to 20 mg/kg IV NP137 every two weeks were well tolerated with no dose-limiting toxicities (DLTs) reported in a Phase I trial in 19 patients...
BioCentury | Sep 14, 2018
Clinical News

Merck's Zerbaxa non-inferior to meropenem in Phase III for bacterial pneumonia

...& Co. Inc. (NYSE:MRK) said Zerbaxa ceftolozane/tazobactam met the primary endpoints in the Phase III ASPECT-NP...
...rate at the test-of-cure (TOC) visit 7-14 days after the end of treatment. The double-blind ASPECT-NP...
BioCentury | May 11, 2018
Clinical News

Neuraltus' NP001 fails Phase II for ALS

Neuraltus Pharmaceuticals Inc. (San Bruno, Calif.) said NP001 missed the primary and secondary endpoints in a Phase II trial to treat amyotrophic lateral sclerosis (ALS). Data were presented at the American Academy of Neurology meeting...
BioCentury | Mar 30, 2018
Clinical News

AMO Pharma reports Phase II data for myotonic dystrophy candidate

...myotonic dystrophy type 1 (DM1) Endpoint: Safety Status: Phase II data Milestone: NA Jennie Walters tideglusib (AMO-02, np-12...
Items per page:
1 - 10 of 281